Loading... Please wait...


Our Newsletter

AMD3100 (Plerixafor) | HIV-1 entry blocker

  • AMD3100 (Plerixafor).jpg
  • AMD3100 (Plerixafor), 400x400px, png
Catalog #:

Product Description

Plerixafor (AMD3100) is a bis-tetraazadecane-based, selective inhibitor of human immunodeficiency virus. It is inhibitory to the replication of various HIV-1 and HIV-2 strains in various cell lines at an EC50 of 1-10 ng/mL, about 100,000-fold lower than cytotoxic concentrations (>500 uM/mL). [1] Plerixafor shows inhibition to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/mL.

Plerixafor has been shown to be active in HIV strains resistant to reverse transcriptase inhibitors AZT, DDI, 3TC, aAPA, and TIBO. [2]

Plerixafor blocks HIV-1 entry and membrane fusion via the CXCR4 co-receptor, but not via CCR5. It also prevents monoclonal antibody 12G5 from binding to CXCR4. Entry into CXCR-expressing cells was strongly inhibited by Plerixafor at IC50 values of 0.01-0.1 nM. [3] Plerixafor demonstrates a specific antagonism of the interaction between chemokine SDF-1 and CXCR4, reducing severity of inflammation in CIA models. [4]

Technical information:

Chemical Formula:   C28H54N8
CAS #:   110078-46-1, 155148-31-5
Molecular Weight:   502.78
Purity:   > 98%
Appearance:   White
Chemical Name:   1,1'-[1,4-Phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane]
Solubility:   Up to 100 mM in water in DMSO
Synonyms:   AMD3100, AMD 3100, Plerixafor, Mozobil, bicyclam JM-2987

Shipping Condition: The product is shipped in a glass vial at ambient temperature.
Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.


1. De Clercq et al., Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 1994, 38(4), 668-674. Pubmed ID: 7913308
2. Este et al., Antiviral activity of the bicyclam derivative JM3100 against drug-resistant strains of human immunodeficiency virus type 1. Antiviral Res. 1996, 29, 297-307. Pubmed ID: 8739608
3. Donzella et al., AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nature Med. 1998, 4(1), 72-77. Pubmed ID: 9427609
4. Matthys et al., AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J. Immunol. 2001, 167(8), 4686-4692. Pubmed ID: 8739608

Other Information:

Product Specification (pdf)
MSDS (pdf)
Certificate of Analysis is available upon request.

Find Similar Products by Category

Write your own product review

Product Reviews

This product hasn't received any reviews yet. Be the first to review this product!

Add to Wish List

Click the button below to add the AMD3100 (Plerixafor) | HIV-1 entry blocker to your wish list.

You Recently Viewed...